Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 18
---
 in the Series D Certificate of Designations) assuming an Alternate Conversion Date (as defined in the Series D Certificate of Designations) of such date of determination, and (y) any such conversion shall not take into account any limitations on the conversion of the Series D Preferred Stock set forth in the Series D Certificate of Designations). Keystone Equity Financing In February 2024, we entered into the February 2024 Keystone Purchase Agreement with Keystone, pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $25,000,000 of shares of Common Stock (the “Keystone Purchase Shares”); provided that the number of shares issued pursuant to the February 2024 Keystone Purchase Agreement shall not exceed 250,000 shares (the “Initial Limit”). As consideration for Keystone’s commitment to purchase shares of Common Stock pursuant to the Keystone Purchase Agreements, we issued an aggregate of 19,833 shares of Common Stock to Keystone (the “Keystone Commitment Shares”). As of the date of this prospectus, we have issued and sold 23,377,921 shares of Common Stock for aggregate proceeds of $4,410,616 under the Keystone Equity Financing. We previously filed a registration statement on Form S-1 (File No. 333-278603), which was declared effective by the SEC on May 1, 2024, and remains in effect (the “Prior Registration Statement”), with respect to up to (i) 250,000 Keystone Purchase Shares and (ii) 6,190 Keystone Commitment Shares. In November 2024, in order to enable us to issue and sell additional shares in excess of the Initial Limit and up to $25,000,000, we entered into the November 2024 Keystone Purchase Agreement with Keystone, pursuant to which we may issue and sell up to $20,589,384 of shares of Common Stock. As of the date of this prospectus, we have issued and sold 708,407 November 2024 Keystone Purchase Shares (as defined below) for aggregate proceeds of $2,623,788 and 1,377,950 November 2024 Keystone Purchase Shares remain available for issuance under the November 2024 Keystone Purchase Agreement. We do not have a right to commence any sales of Common Stock to Keystone under the November 2024 Keystone Purchase Agreement until the time when all of the conditions to our right to commence sales of Common Stock to Keystone set forth in the November 2024 Keystone Purchase Agreement have been satisfied